CANCER

Extensive Oncology Platform

Vivasor’s multimodal and multipronged approach to fighting cancer is made possible by our extensive oncology platforms and fully human G-MAB™ (G-Monoclonal Antibody) library. Vivasor’s proprietary G-MAB™ technology was invented by CEO Dr. Henry Ji and is one of the largest fully human antibody libraries in the biopharmaceutical industry. Thus far, Vivasor has successfully identified fully human antibodies against over 100 clinically relevant high-impact oncogenic targets.

Next area of focus

COVID-19

Multimodal Approach – Prevention and Treatment Continuum

Vivasor is focused on creating innovative solutions to combat the Covid-19 virus with solutions to detect and treat Covid-19. Check out our key programs below to learn more about what we are doing to combat the pandemic.

Next area of focus

PAIN

Innovative Non-Opioid Pain Therapeutics

Vivasor commitment to life-enhancing therapies for patients is demonstrated by our effort to advance non-opioid pain management. From our currently marketed ZTlido® (lidocaine topical system1.8%) to our development of resiniferatoxin (“RTX”) and SP-102 (SEMDEXA™), we are committed to commercializing novel therapies that meet patient needs safely and effectively.

Next area of focus

DIAGNOSTICS

Detect Early, Treat Timely, Save Lives.

Vivasor’ Diagnostic development leverages our proprietary G-MAB™ library to screen and select antibodies to generate high-sensitivity diagnostics. From our currently marketed COVID-19 rapid antigen test COVIMARKTM, to our next-generation diagnostic platform VIRTTUTM, our goal is to enable people to detect early and treat timely.

Next area of focus